Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced ...

The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are ...

All presentations will be made available on the "News & Events," page in the Investors section of the Company's website at https://ir.metagenomi.co/news-events/events.